Scholarlink

Background <p>High grade gliomas are aggressive intrinsic brain tumors with limited treatment options and a universally poor prognosis. In recent years, significant progress has been made in understanding the genetic and molecular underpinnings of high grade gliomas and their interactions with the tumor microenvironment, including vasculature, immune cells, neurons, and glia, and, consequently, in the development of novel molecularly targeted therapies and immunotherapies.</p> Methods <p>Here, we review ongoing work in the clinical development of new therapeutic strategies for high grade gliomas, discuss ongoing challenges, and highlight emerging opportunities for targeted intervention, with particular focus on molecularly targeted and immunotherapy in recent and ongoing clinical trials.</p> Results <p>We discuss relevant molecular targets in high grade glioma, including IDH, VEGF, RTK signaling (EGFR, PI3K/Akt, Ras/Raf/MEK), p53, CDKN2A/B, CDK4/6, MGMT, PARP, TERT, and ATRX, as well as contemporary immunotherapeutic strategies including immune checkpoint inhibition (including classical and emerging targets), cell-based immunotherapy (CAR-T cells, TCR therapy, TIL therapy, and other engineered cell therapies), cancer vaccines, oncolytic viruses, as well as emerging mechanisms including cancer neuroscience-based therapies.</p> Conclusions <p>High grade glioma is a networked disease, involving numerous interconnected molecular and microenvironmental phenomena from tumor-intrinsic pathways and antigenicity to immune recognition and attack to neuronal modulation of both tumor and immune signaling. Emerging therapies harness several of these intersectional mechanisms, often simultaneously, and together offer hope for the future of clinical treatment of these devastating cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunotherapy and targeted therapy for high grade gliomas: current and future directions

  • 期刊论文

  • 发表日期：

    2025年12月9日

查看全文
  • Brian Hsueh,
  • Samuel J. Steuart,
  • Angel O. Odukoya,
  • Briana C. Prager,
  • Young Joon Kim,
  • Cameron M. Hill,
  • Bryan D. Choi,
  • Gavin P. Dunn

摘要

Background

High grade gliomas are aggressive intrinsic brain tumors with limited treatment options and a universally poor prognosis. In recent years, significant progress has been made in understanding the genetic and molecular underpinnings of high grade gliomas and their interactions with the tumor microenvironment, including vasculature, immune cells, neurons, and glia, and, consequently, in the development of novel molecularly targeted therapies and immunotherapies.

Methods

Here, we review ongoing work in the clinical development of new therapeutic strategies for high grade gliomas, discuss ongoing challenges, and highlight emerging opportunities for targeted intervention, with particular focus on molecularly targeted and immunotherapy in recent and ongoing clinical trials.

Results

We discuss relevant molecular targets in high grade glioma, including IDH, VEGF, RTK signaling (EGFR, PI3K/Akt, Ras/Raf/MEK), p53, CDKN2A/B, CDK4/6, MGMT, PARP, TERT, and ATRX, as well as contemporary immunotherapeutic strategies including immune checkpoint inhibition (including classical and emerging targets), cell-based immunotherapy (CAR-T cells, TCR therapy, TIL therapy, and other engineered cell therapies), cancer vaccines, oncolytic viruses, as well as emerging mechanisms including cancer neuroscience-based therapies.

Conclusions

High grade glioma is a networked disease, involving numerous interconnected molecular and microenvironmental phenomena from tumor-intrinsic pathways and antigenicity to immune recognition and attack to neuronal modulation of both tumor and immune signaling. Emerging therapies harness several of these intersectional mechanisms, often simultaneously, and together offer hope for the future of clinical treatment of these devastating cancers.